EDEN PRAIRIE, Minn., March 07, 2018 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq:CHFS), today announces that it
will be exhibiting at the 67th Annual Scientific Sessions of the American College of Cardiology (ACC) from March 10-12
in Orlando, Florida.
The company will be exhibiting its Aquadex FlexFlow System and can be found on the exhibition floor at the Orange County
Convention Center, Booth #1505 during the conference.
“Attending the ACC Conference is an important venue to demonstrate the clinical and economic value of our Aquadex FlexFlow
System. We look forward to connecting with the Cardiology community at the ACC Conference and further educating the
attendees on the value of our Ultrafiltration System,” said Jim Breidenstein, chief commercial officer of CHF Solutions.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for
Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of
patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of
patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a
healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's
mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical
technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly
owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market
since February 2012.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com
